Oslo Pensjonsforsikring AS Takes Position in Eli Lilly and Company $LLY

Oslo Pensjonsforsikring AS acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,971 shares of the company’s stock, valued at approximately $2,733,000. Eli Lilly and Company makes up about 0.4% of Oslo Pensjonsforsikring AS’s holdings, making the stock its 23rd largest holding.

A number of other hedge funds also recently bought and sold shares of LLY. Maryland Capital Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $25,000. Osbon Capital Management LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $30,000. Maseco LLP grew its holdings in shares of Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after purchasing an additional 28 shares during the last quarter. Finally, E Fund Management Hong Kong Co. Ltd. grew its holdings in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 2.5%

Shares of LLY opened at $1,175.15 on Wednesday. The stock has a market capitalization of $1.11 trillion, a P/E ratio of 41.75, a PEG ratio of 1.44 and a beta of 0.51. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The firm has a fifty day simple moving average of $1,126.19 and a two-hundred day simple moving average of $1,037.68.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 34.55 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Wall Street Analyst Weigh In

Several research firms have weighed in on LLY. Weiss Ratings raised shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. The Goldman Sachs Group reaffirmed a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Bank of America lifted their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. JPMorgan Chase & Co. boosted their target price on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Finally, Citigroup increased their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Several market commentary pieces highlighted Lilly’s leadership in GLP-1 obesity treatments, its expanding pipeline, and the view that its growth outlook remains strong despite intensifying competition from Novo Nordisk.
• Positive Sentiment: Analyst-focused coverage continued to point to Lilly’s momentum from Zepbound and Mounjaro, with investors still treating the company as a core winner in the fast-growing weight-loss and diabetes market.
• Positive Sentiment: Broader healthcare stocks also moved higher, which likely provided a supportive backdrop for Eli Lilly shares during the session.
• Neutral Sentiment: Eli Lilly defended its advertising, saying its comparisons are based on the SURMOUNT-5 trial, while noting Novo’s criticism centers on the use of older dose comparisons rather than direct head-to-head data.
• Negative Sentiment: Novo Nordisk sued Eli Lilly in U.S. federal court, accusing the company of false and misleading advertising for Zepbound and Mounjaro and seeking to stop the ads, force corrective marketing, and recover damages. Reuters article about the lawsuit

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.